Novo Nordisk Launches Oral Wegovy Pill Against Eli Lilly

What happened

Novo Nordisk launched the first oral version of Wegovy, its blockbuster weight-loss drug, in January and reported the pill has already reached more than 5 million prescriptions in the U.S. The company also rolled out a higher-dose version of the Wegovy injection during the first half of 2026, expanding treatment options for patients. Second-quarter sales totalled 78.49 billion Danish crowns (approximately $12.09 billion), representing a 3% increase at constant exchange rates, or 7% on an adjusted basis. Adjusted operating profit rose 11% at constant exchange rates to 33.39 billion crowns, ahead of analyst forecasts. Novo Nordisk raised its full-year 2026 outlook, now expecting adjusted sales to range from a 6% decline to flat growth, improving from earlier guidance of a 4% to 12% decline.

Why it matters

The oral Wegovy launch represents a significant competitive move in the obesity drug market, positioning Novo Nordisk ahead of rival Eli Lilly in delivering a pill-based GLP-1 treatment. Investors view the Wegovy pill rollout as a key indicator of whether Novo Nordisk can maintain its leadership in obesity therapeutics amid growing competition. The product's rapid prescription uptake demonstrates strong physician and patient demand for oral alternatives to injections. However, the company's cautious 2026 outlook-projecting potential sales and profit declines-signals management expects continued pressure from Eli Lilly's competing products, Zepbound and Mounjaro, which have captured significant market share.

Bigger picture

The GLP-1 drug market for obesity and diabetes has become one of the most competitive and lucrative segments in pharmaceuticals. Novo Nordisk had dominated with its injectable Wegovy and Ozempic brands, but Eli Lilly has gained ground rapidly with its newer treatments. By launching the first oral GLP-1 obesity pill, Novo Nordisk is working to differentiate its portfolio and recapture momentum. The higher-dose Wegovy injection further expands treatment options, giving the company multiple pathways to serve different patient preferences. Both companies are expected to report quarterly earnings on the same day, intensifying investor focus on comparative performance in this fast-growing therapeutic area.

What to watch

Investors will closely monitor prescription trends for the oral Wegovy pill to assess whether demand continues accelerating beyond the initial 5 million prescriptions. Comparative sales performance between Novo Nordisk and Eli Lilly's competing products will be critical, especially as both companies report quarterly results simultaneously. Full-year 2026 financial performance will test whether Novo Nordisk's expanded portfolio can stabilise or grow sales against earlier projections of potential declines. Additionally, any updates on manufacturing capacity, supply constraints, or new obesity treatment formulations will influence the competitive dynamics in the GLP-1 market.